Selected Publications from 2017

Publications

Effect of second timed appointments for non-attenders of breast cancer screening in England: a randomised controlled trial
Allgood PC, Maroni R, Hudson S, Offman J, Turnbull AE, Peacock L, Steel J, Kirby G, Ingram CE, Somers J, Fuller C, Threlfall AG, Gabe R, Maxwell AJ, Patnick J, Duffy SW
Lancet Oncol  2017  18(7)  972-980
 
Interrogating open issues in cancer precision medicine with patient-derived xenografts
Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, et al.
Nature Reviews Cancer  2017  17(4)  254-268
 
TACT2 Investigators. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial
Cameron D, Morden JP, Canney P, Velikova G, Coleman R, Bartlett J, Agrawal R, Banerji J, Bertelli G, Bloomfield D, Brunt AM, Earl H, Ellis P, Gaunt C, Gillman A, Hearfield N, Laing R, Murray N, Couper N, Stein RC, Verrill M, Wardley A, Barrett-Lee P, Bliss JM
Lancet Oncol  2017  18(7)  929-945
 
Challenges in enumeration of CTCs in breast cancer using techniques independent of cytokeratin expression
Castle J, Morris K, Pritchard S, Kirwan CC
PLoS One  2017  12(4) 
 
tAnGo trial collaborators. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial
Earl HM, Hiller L, Howard HC, Dunn JA, Young J, Bowden SJ, McDermaid M, Waterhouse AK, Wilson G, Agrawal R, O'Reilly S, Bowman A, Ritchie DM, Goodman A, Hickish T, McAdam K, Cameron D, Dodwell D, Rea DW, Caldas C, Provenzano E, Abraham JE, Canney P, Crown JP, Kennedy MJ, Coleman R, Leonard RC, Carmichael JA, Wardley AM, Poole CJ
Lancet Oncol  2017  18(6)  755-769
 
The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study
Evans DG, Brentnall A, Byers H, Harkness E, Stavrinos P, Howell A; FH-risk study Group., Newman WG, Cuzick J
J Med Genet  2017  54(2)  111-113
 
The RAZOR trial: a phase II prevention trial of screening plus goserelin and raloxifene versus screening alone in pre-menopausal women at increased risk of breast cancer
Howell A, Ashcroft L, Evans DG, Dowsett M, Cuzick J, Eccles D, Eeles R, Greenhalgh R, Affen J, Bundred S, Boggis C, Sergeant J, Fallowfield L and Adams J
Cancer Prevention Epidemiology and Biomarkers in press  2017   
 
Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: Real world experience in Greater Manchester, UK
Loncaster J, Armstrong A, Howell S, Wilson G, Welch R, Chittalia A, Valentine WJ, Bundred NJ
Eur J Surg Oncol  2017  43(5)  931-937
 
False-negative MRI breast screening in high-risk women
Maxwell AJ, Lim YY, Hurley E, Evans DG, Howell A, Gadde S
Clin Radiol  2017  72(3)  207-216
 
A randomised trial of screening with digital breast tomosynthesis plus conventional digital 2D mammography versus 2D mammography alone in younger higher risk women
Maxwell AJ, Michell M, Lim YY, et al.
Eur J Radiol  2017   
 
Recruitment to the "Breast-Activity and Healthy Eating After Diagnosis" (B-AHEAD) Randomized Controlled Trial
Pegington M, Adams JE, Bundred NJ, Campbell AM, Howell A, Howell SJ, Speed S, Wolstenholme J, Harvie MN
Integr Cancer Ther  2017   
 
Preoperative implant selection for unilateral breast reconstruction using 3D imaging with the Microsoft Kinect sensor
Pöhlmann STL, Harkness E, Taylor CJ, Gandhi A, Astley SM
J Plast Reconstr Aesthet Surg  2017  23 
 
Results from the BRIOS randomised trial
Potter S, Wilson RL, Harvey J, Holcombe C, Kirwan CC
Lancet Oncol  2017  18(4) 
 
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P
N Engl J Med  2017   
 
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L
Ann Oncol  2017  28(1)  128-135
 
Cellular mechano-environment regulates the mammary circadian clock
Yang N, Williams J, Pekovic-Vaughan V, Wang P, Olabi S, McConnell J, Gossan N, Hughes A, Cheung J, Streuli CH*, Meng Q-J*
Nature Communications  2017  8 
 


Seminars